![]() ![]() |
AVEO PharmaceuticalsAVEO is a biopharmaceutical company focused on the discovery and development of drugs that target gene products critical for the maintenance and recurrence of established cancers. AVEO is positioned to revolutionize cancer drug discovery and development by employing powerful, proprietary genetic model systems to discover and develop drugs against essential targets critical to the origin, maintenance and spread of malignant tumors. This novel high-throughput in vivo technology platform enables the rapid functional identification and prioritization of only the most relevant drug targets – dramatically improving the efficiency of drug discovery. Additionally, by identifying patient populations likely to be responsive to drug therapy, AVEO’s technology enables smarter drug development, decreased development costs and improved attrition. Recent NewsAVEO Pharmaceuticals’ Novel Triple VEGF Receptor Inhibitor Shows Tumor Regression in Patients with Advanced Renal CancerAVEO Pharmaceuticals Appoints Kenneth M. Bate to Board of DirectorsAVEO Pharmaceuticals to Present at 26th Annual JPMorgan Healthcare ConferenceAVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response ProjectAVEO Pharmaceuticals to Present at Lazard Capital Markets 4th Annual Healthcare ConferencePreclinical Data Published in Cancer Science Show AVEO's Novel Oral EGFR Inhibitor AV-412 Effective in Drug-Resistant CancersResults from Phase 1 Study of AVEO’s Novel Triple VEGF Receptor Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved Partial Response or Stable Disease |
![]() CEOTuan Ha-NgocContact Info75 Sydney Street4th Floor Cambridge, Massachusetts 02139 Phone: 617.299.5000 Fax: 617.995.4995 Key LinksWebsiteJobs Info Highland Team Bob Higgins
|